Posted by Site Administrator on March 1, 2013
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
From the UKMND-LiCALS Study Group
Summary article posted online in The Lancet Neurology, February 27, 2013 •
Background
Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a [...]
Categories: Clinical Trials, Research News, Treatments
| 
Tags: ALS clinical trial, ALS medical care, ALS research, ALS research funding, ALS treatment research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, LiCALS trial, lithium ALS treatment, lithium carbonate, PALS, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, The Motor Neurone Disease Association of Great Britain and Northern Ireland
| 
No comments
Posted by Site Administrator on January 15, 2013
“Some may look at recent failures and be discouraged,” wrote Richard Bedlack of the Duke ALS Clinic in Durham, North Carolina, in an e-mail to Alzforum. Thanks to advances in genetics and biomarkers, and a list of potential target pathways, “I think this is a time of unprecedented hope and excitement in ALS research”
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS clinical trials, ALS community, ALS Functional Rating Scale (ALSFRS), ALS Phase 3 studies, ALS research, ALS research funding, ALS sodium chlorite, ALS TDI, ALS Therapy Development Institute, ALS treatments, amyotrophic lateral sclerosis, Angela Genge, Annual Symposium on Amyotrophic Lateral Sclerosis/Motor Neuron Disease, antisense oligonucleotide therapy ALS, astrocyte excitatory amino acid transporter 2, Benjamin Brooks, Biogen Idec, biomarkers ALS, Bob Stehlin, ceftriaxone, CK-2017357, cytochrome P450 1A2, Cytokinetics, dexpramipexole, Dr. Timothy Miller, Duke ALS Clinic Durham, Emory University Atlanta, Evan Snyder, FDA, fingolimod, Food and Drug Administration, Forbes Norris MDA/ALS Research Center, genetics ALS, Gilenya, immune-system drugs ALS, Inc., ISIS 333611, Isis Pharmaceuticals, Jeremy Shefner, Jonathan Glass, Les Turner ALS Foundation, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, mitochondrial modulator, Montréal Neurological Institute and Hospital, mutant human superoxide dismutase 1, mutant superoxide dismutase 1, Neil Cashman, Neuralstem Inc, Neuraltus, North Carolina, Northeast ALS Consortium, Novartis, NP001, olesoxime, oligonucleotide, oligonucleotide ALS, oligonucleotide via intrathecal infusion, PALS, Phase III trial ALS, Pitié-Salpêtrière Hospital, RASCALS Foundation, Richard Bedlack, riluzole, Robert A. Stehlin Campaign for ALS, Robert Brown, Robert Miller, Sanford-Burnham Medical Research Institute, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York Upstate Medical University, stem cell trial ALS, Steven Perrin, Susanna Benn, synaptic glutamate, target pathways ALS, Tim Miller, Timothée Lenglet, Tirasemtiv, troponin ALS, University of British Columbia, University of Massachusetts Medical School Worcester, University of North Carolina School of Medicine, Washington University St. Louis, Wendy Abrams, Yang Teng, Yang Teng of Brigham and Women’s Hospital
| No comments
Posted by Site Administrator on December 10, 2012
While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed
Categories: Clinical Trials, Research News, Treatments
| Tags: 20th International Symposium on ALS/MND, 501(c)(3) ALS charity, AAD 2004, Adult stem cells, ALS, ALS community, ALS medical care, ALS research, ALS treatments, ALSFRS-R, AmKor Pharma, amyotrophic lateral sclerosis, anti-inflammatory effects ALS, antioxidative effects ALS, Arimoclomol, Aß plaque, Bensimon, Biogen Idec, Biorex, Bob Stehlin, Brainstorm, BrainStorm Cell Therapeutics, Cell replacement therapies, dexpramipexole, dopamine receptor, Edaravone, Edaravone IV injection, EMPOWER, fast-track status, FDA, FDA fast-track designation, GNDF-producing adult stem cell therapy, GNT Pharma, Hadassah Medical Center, Hadassah Medical Center Israel, hydroxylamine derivative, inhibition and reduction of beta-amyloid (Aß) peptide levels, Knopp Biosciences, lipoperoxide 15-HPETE, Lou Gehrig's disease, Mitsubishi Tanabe Pharma, NCT01281189, NCT01492686, Neuralstem, neuroprotection, NSI 566RSC, NurOwn, Orphazyme ApS, PALS, Phase I trial, Phase II clinical trial, Phase III trial, PNA Center for Neurological Research, pramipexole, Radicut, RASCALS Foundation, Revised ALS Functional Rating Scale, Rilutek, riluzole, Robert A. Stehlin Campaign for ALS, Sanofi, SOD1, Spinal Cord Delivery Platform and Floating Cannula, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, stem cells, Synthetic Biologics, TCA Cellular Therapy, Tel Aviv University, University of Miami
| No comments
Posted by Site Administrator on November 10, 2012
“Patients who suffer from this devastating disease are in critical need of a novel therapy that addresses the functional deficits that limit their activities of daily living,” stated Jeremy M. Shefner, MD, PhD, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York and Principal Investigator of BENEFIT-ALS. “If successful, this novel mechanism therapy could improve the lives of many patients living with ALS.”
Categories: Clinical Trials, Research News, Treatments
| Tags: ALS, ALS community, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), Bob Stehlin, CK-2017357, CY 4026, Cytokinetics Incorporated, Department of Neurology at the Upstate Medical University at the State University of New York, FDA ALS, Jeremy M. Shefner MD PhD, Lou Gehrig's disease, Phase II clinical trial, Phase IIb, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, skeletal muscle troponin complex, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, State University of New York, Tirasemtiv
| No comments
Posted by Site Administrator on May 24, 2012
Current treatment of ALS is aimed at symptomatic relief, prevention of complications and maintenance of maximum optimal function and optimal quality of life.
Categories: 501(c)(3) Non-Profit, Caretakers, Treatments
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, Lou Gehrig’s disease, PALS, RASCALS Foundation, Rilutek, riluzole, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on January 9, 2012
Results of the first stage showed that receiving dexpramipexole appeared to slow the progression of symptoms measured both by the ALS Functional Rating Scale and by pulmonary capacity. The second stage had similar results, with slower disease progression and a reduced risk of death in participants receiving the higher dosage.
Categories: Research News
| Tags: ALS, ALS community, amyotrophic lateral sclerosis, Biogen Idec, California Pacific Medical Center, Columbia University Medical Center, Craig Amburgey, Dan Moore, David Schoenfeld, dexpramipexole, Donald Archibald, Evan Ingersoll, Hiroshi Mitsumoto, James Mather, Jeremy Shefner, Juliet Moritz, Knopp Biosciences, Lou Gehrig's disease, Mary Sullivan, Massachusetts General Hospital, Massachusetts General Hospital (MGH) Neurology Clinical Trials Unit and ALS Center, Merit Cudkowicz MD, MGH Biostatistics, Michael Bozik, Mitochondrial dysfunction, neurodegenerative disease, Northeast ALS Consortium, Nuedexta, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, Robert Miller, State University of New York Upstate Medical University Syracuse, Valentin Gribkoff PhD
| No comments
